Phase II Trial of Concurrent Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab (Avastin) in the Treatment of Patients With Limited Stage Small Cell Lung Cancer
Upon determination of eligibility, all patients will be receive:
- Irinotecan + Carboplatin + Radiation Therapy + Bevacizumab
Patients will receive 4 courses of irinotecan/carboplatin. Radiation therapy will begin
concurrently with the third course of chemotherapy. The intervals between chemotherapy
courses will be 21 days except for the interval between the third and fourth courses (during
radiation therapy), which will be 28 days.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of Grade 3/4 Toxicities Patients Experienced on Maintenance Bevacizumab Following Chemoradiation for Limited Stage - Small Cell Lung Cancer (LS-SCLC)
Toxicity was evaluated in all patients who received at least 1 dose of therapy, and graded according to CTCAE v. 3.
John D. Hainsworth, MD
Sarah Cannon Research Institute
United States: Food and Drug Administration
SCRI LUN 72